CN107951550A - A kind of degradable inner membrane of uterine cavity implant system - Google Patents
A kind of degradable inner membrane of uterine cavity implant system Download PDFInfo
- Publication number
- CN107951550A CN107951550A CN201711340775.3A CN201711340775A CN107951550A CN 107951550 A CN107951550 A CN 107951550A CN 201711340775 A CN201711340775 A CN 201711340775A CN 107951550 A CN107951550 A CN 107951550A
- Authority
- CN
- China
- Prior art keywords
- implant
- uterine cavity
- inner membrane
- implant system
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007943 implant Substances 0.000 title claims abstract description 62
- 239000012528 membrane Substances 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 28
- 239000011159 matrix material Substances 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000000758 substrate Substances 0.000 claims abstract description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 32
- 229960005309 estradiol Drugs 0.000 claims description 18
- 108010025899 gelatin film Proteins 0.000 claims description 10
- 238000009513 drug distribution Methods 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 210000004291 uterus Anatomy 0.000 abstract description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 12
- 208000028685 Asherman syndrome Diseases 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 229960000905 indomethacin Drugs 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 239000004626 polylactic acid Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- ZMKVBUOZONDYBW-UHFFFAOYSA-N 1,6-dioxecane-2,5-dione Chemical compound O=C1CCC(=O)OCCCCO1 ZMKVBUOZONDYBW-UHFFFAOYSA-N 0.000 description 1
- 101100021395 Arabidopsis thaliana LIP1 gene Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- LKFHUFAEFBRVQX-UHFFFAOYSA-N decanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCCCCCCCC(O)=O LKFHUFAEFBRVQX-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- -1 poly butylene succinate Polymers 0.000 description 1
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920002796 poly[α-(4-aminobutyl)-L-glycolic acid) Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920002961 polybutylene succinate Polymers 0.000 description 1
- 239000004631 polybutylene succinate Substances 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B2017/4216—Operations on uterus, e.g. endometrium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/14—Female reproductive, genital organs
- A61M2210/1433—Uterus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Medicinal Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
Abstract
The present invention relates to a kind of degradable inner membrane of uterine cavity implant system, including delivery pipe, push rod and implant, at least part push rod is contained in delivery pipe, implant is contained in delivery pipe and receives the promotion of push rod in the first state, implant is the membranaceous or laminated structure with medicine, implant includes the medicine of the matrix and load of biodegradable material on the substrate, and the through hole for connecting membranaceous or laminated structure both sides is provided with matrix.Degradable inner membrane of uterine cavity implant system according to the present invention, the commitment positions being placed in implant by means of push rod in uterine cavity body, the uterine veil of adhesion is isolated by the matrix of implant and supporting role, the inflammation and wound face on uterus surface are effectively repaired by the medicine of implant, wherein, which alleviates due to being taken out without the later stage and operates the pain caused by sufferer repeatedly.
Description
Technical field
The present invention relates to uterine cavity implantation instrument, relates more specifically to a kind of degradable inner membrane of uterine cavity implant system.
Background technology
Occurring for women Asherman's syndrom may be with the pregnant or non-pregnant factor of uteroventral operation history, and operation inflammatory factor
Related etc. reason, Asherman's syndrom brings the even infertile pain of menstrual disorder directly to women.In order to be carried out to Asherman's syndrom
Treatment, the means of the prior art are often complex and heavy financial burden is brought to patient.
The content of the invention
In order to solve the problems, such as the high cost of above-mentioned treatment Asherman's syndrom existing in the prior art, the present invention is intended to provide
A kind of degradable inner membrane of uterine cavity implant system.
Degradable inner membrane of uterine cavity implant system of the present invention, including delivery pipe, push rod and implant, at least partly
Push rod is contained in delivery pipe, and implant is contained in delivery pipe and receives the promotion of push rod in the first state, and implant is
Membranaceous or laminated structure with medicine, implant include the medicine of the matrix and load of biodegradable material on the substrate, base
The through hole for connecting membranaceous or laminated structure both sides is provided with matter.
The delivery pipe is circular tube structure, its madial wall is formed as step wall and limits the major diameter cavity of connection and small
Diameter cavity.
Push rod is straight-bar structure, including the first enlarged diameter section, reduced diameter section and the second enlarged diameter section, wherein, reduced diameter section
Between the first enlarged diameter section and the second enlarged diameter section, and the first enlarged diameter section is contained in major diameter cavity and coordinates.
Implant is ▽ types, Y types, orType.
Matrix is the gelatin film or independent gelatin film being supported on degradable skeleton.
Degradable skeleton is V-type.
Through hole is with the evenly spaced distribution of 2mm-3mm.
A diameter of 2mm-3mm of through hole.
- 7 exhausting hole of 5 row is set in matrix.
Indomethacin joint is blended for 17- β estradiol in medicine；Or single 17- β estradiol.
The daily burst size of medicine is 20-200 μ g.
Drug distribution is in the inside of matrix.
Implant, is placed in uterine cavity body by degradable inner membrane of uterine cavity implant system according to the present invention by means of push rod
Commitment positions, the uterine veil of adhesion is isolated by the matrix of implant and supporting role, passes through the medicine of implant
Inflammation and wound face to uterus surface are effectively repaired, wherein, which not only can be at 0.5 to 2
Month deenergized period interior orientation quantitatively slowly into uterine cavity wound face and inflammation administration with carry out continue and effectively repair with
Solve the problems, such as Asherman's syndrom, and alleviate due to being taken out without the later stage and operate the pain caused by sufferer repeatedly.
Brief description of the drawings
Fig. 1 is the schematic perspective view of inner membrane of uterine cavity implant system degradable according to the present invention；
Fig. 2 is the schematic cross-sectional view of inner membrane of uterine cavity implant system degradable according to the present invention；
Fig. 3 shows the implant in Fig. 1；
Fig. 4 is the schematic diagram of another implant according to the present invention.
Embodiment
Below in conjunction with the accompanying drawings, presently preferred embodiments of the present invention is provided, and is described in detail.
Fig. 1-Fig. 2 shows inner membrane of uterine cavity implant system degradable according to the present invention, including delivery pipe 1,2 and of push rod
Implant 3.In the present embodiment, delivery pipe 1 is circular tube structure, its madial wall is formed as step wall and limits the big of connection
Diameter cavity 11 and minor diameter cavity 12.Push rod 2 is straight-bar structure, including the first enlarged diameter section 21, reduced diameter section 22 and second
Enlarged diameter section 23, wherein, reduced diameter section 22 is between the first enlarged diameter section 21 and the second enlarged diameter section 23, and the first major diameter
The diameter of section 21 is slightly less than the second enlarged diameter section 23.In the present embodiment, which is contained in major diameter cavity
Coordinate in 11.Implant 3 is the membranaceous or laminated structure with medicine, it is contained in major diameter cavity 11 and can pushing away in push rod 2
Released under dynamic from delivery pipe 1.
During specifically used, the step wall of the first enlarged diameter section 21 of push rod 2 towards delivery pipe 1 is drawn first
Go out so that the first enlarged diameter section 21 of push rod 2 in the major diameter cavity 11 against the step surface of delivery pipe 1, then will plant
Enter thing 3 to be positioned in the major diameter cavity 11 of delivery pipe 1, the inner membrane of uterine cavity implant system is next arranged at appropriate position
Put, promote push rod 2 towards implant 3 so that push rod 2 promotes the commitment positions that implant 3 is arrived in uterine cavity body, and can be with medicine
Thing discharges.
The implant 3 is up-side down triangle, i.e. ▽ types.In fact, according to the profile in uterus, which can also basis
Need to be adjusted to Y types orType etc..
The implant 3 includes the medicine of matrix and load on the substrate.So, on the one hand, the matrix of implant 3 can be with
The uterine veil of adhesion is isolated and supporting role, on the other hand, the medicine of implant 3 can to the inflammation on uterus surface and
Wound face is effectively repaired.
Matrix is biodegradable material.Preferably, in the period of 0.5~2 month of implant 3 after the implantation periodically
Degraded, is not required to take out.In this way, not only 0.5 to 2 months deenergized period interior orientation quantitatively slowly into uterine cavity wound face and
Inflammation administration is continued with carrying out and effectively repaired to solve the problems, such as Asherman's syndrom, and alleviate to operate repeatedly to make sufferer
Into pain.
In one embodiment, the matrix of implant 3 is the gelatin film 32 being supported on degradable skeleton 31, such as Fig. 3 institutes
Show.Wherein, which is rendered as V-type, to be supported to gelatin film 32, prevents gelatin film 32 in implantation process
With the curling after implantation.In another embodiment, the matrix of implant 3 can be omitted degradable skeleton 31 and only by gelatin
Film 32 is formed, as shown in Figure 4.
The degradable skeleton 31 of implant 3 can be formed by any degradation material, include but not limited to polylactic acid
(polylactic acid, PLA), l-polylactic acid (polyLlactic acid, PLLA or LPLA), polyglycolic acid/polylactic acid
Copolymer (polyglycolic acid/polylactic acid, PGLA), polycaprolactone (polycaprolactone,
PCL), polyhydroxybutyrate valerate (polyhydroxylbutyrate valerate, PHBV), polyacetylglutamic acid
(polyacetylglutamicacid, PAGA), polyorthoesters (polyorthoesters, POE) and polyethylene glycol oxide/polybutene
Copolymer (polyethylene oxide/polybutylene terephthalate, PEO/PBTP), polydioxanone
(poly-p-dioxanone, PPDO), poly butylene succinate (Poly (butylene succinate), PBS), the poly- last of the ten Heavenly stems two
Acid glyceride (poly (glycerol sebacate), PGS), chitosan, polyvinyl alcohol (Poly Vinyl Alcoho, PVA),
And the copolymer or blend of above-mentioned material, and its homologue.
Through hole 321 is provided with the gelatin film 32 of implant 3, it connects the both sides of film.Preferably, the through hole 321 is with 2mm
Or 3mm is evenly spaced distributed on film, the ventilative of film both sides is realized.
When carrying out the via design of film, the gas permeability of film and film strength are accounted for as two targets, at the same time
Realize the function of this two aspects.The diameter of through hole has been designed as 2mm or 3mm by the experiment of early period, from
Top to bottm designs more exhausting holes, as shown in table 1 below.Come after the completion of via design with two quantitative targets of permeability rate and tensile strength
Investigate the gas permeability and intensity two indices of the film of setting.
Table 1
Experiment shows that the five exhausting holes design of scheme 3 and seven exhausting holes of scheme 4 design, in permeability rate and tensile strength
Two targets delivery rate is high at the same time.If hole is too many, the relative density of film, which reduces tensile strength, to be reduced, and influences film strength
With practical operation feasibility in art.If hole is very little, the gas permeability of film is affected, it is impossible to realizes that the material of film both sides is handed over
Change, influence therapeutic effect.
The medicine of implant 3 can be female hormone, its targeted release repairs the wound face of inflammation or endometrium.According to
The demand of Different Individual, 17- β estradiol 10% Indomethacin of blending that female hormone can be designed as 90% are used in combination；Or
Independent 100% 17- β estradiol is used.Medicine may be designed as having different release behaviors, as shown in table 2 below.
Table 2
| Medicine | Daily burst size | Total drug content |
| 100%17- β estradiol | ≤20μg | 5mg |
| 100%17- β estradiol | ≤50μg | 5mg |
| 100%17- β estradiol | ≤100μg | 5mg |
| 100%17- β estradiol | ≤200μg | 5mg |
| + 10% Indomethacin of 90%17- β estradiol | ≤20μg | 5mg |
| + 10% Indomethacin of 90%17- β estradiol | ≤50μg | 5mg |
| + 10% Indomethacin of 90%17- β estradiol | ≤100μg | 5mg |
| + 10% Indomethacin of 90%17- β estradiol | ≤200μg | 5mg |
The amount of the insoluble drug release can be adhered the degree of adhesion according to uterine cavity, such as slight, the journey of moderate and moderate adhesion
Corresponding burst size is selected after spending different progress type selectings, specifically can slightly select the burst size of 20 μ g or 50 μ g, moderate can
To select the burst size of 100 μ g, severe can select the burst size of 200 μ g.Or according to judgement of the doctor to patient and according to warp
Test use.
The medicine of implant 3 can be loaded in matrix by way of spraying or dip-coating.In one embodiment, by base
Matter is positioned on spraying frame and fixes, and spraying equipment is with 1 μ g/s or 5 μ g/s or suitable spraying rate point spray thing.By nozzle
Film-shaped products are sprayed back and forth, specific time 50s-200s, uniformly covers medicine on film-shaped products, so that real
Now orient the purpose quantitatively discharged.It should be understood that the translational speed of spraying equipment may cause very much to spray uneven soon, speed is too
Slow to influence production efficiency, analysis of experiments 1 μ g/s or 5 μ g/s are a rational velocity interval.In another embodiment,
Matrix is positioned on dip-coating fixed frame and is fixed, fixed frame can be moved up and down with membranaceous implantation instrument, and matrix is complete
It is complete be immersed in medicine after 30s-90s backed off after random containers, wait 5S, after reenter container.The process completes leaching after being repeated 3 times
Technique is applied, uniformly covers medicine in matrix, the purpose quantitatively discharged so as to fulfill orientation.It should be understood that matrix submerges
Overlong time influences production efficiency, and the time too short adhesive force and dose for influencing medicine, is conjunction through analysis of experiments 30s-90s
The spray time of reason；And matrix exits the non-homogeneous immersion distribution of stand-by period too short then medicine of container, stand-by period long shadow
Production efficiency is rung, through analysis of experiments, 5S is a suitable time.In yet another embodiment, the medicine of implant 3 can be
The inside of matrix is distributed in the forming process of matrix, so as to be supported in matrix.For example, by the way that matrix estradiol molecules are molten
The mode of coating film forming is processed making after gelatin solution.The biogelatin solution of configuration 1%~5% first, configures
Under 48 DEG C~52 DEG C parameters, solution will be stirred evenly with certain rotating speed in quantitative estradiol addition solution after, with
After be put into pure-natural biological crosslinking agent Geniposide, continue stirring 1~5 minute, with increase form a film after physical property.Test it
PH value ensures the pH value average of solution near 7.0.Gelatin solution is evenly applied to shape particular design after the completion of test
In polyester base model, it can be taken off being used after film drying.The step can ensure that estradiol uniformly divides in gelatin film
Cloth, to realize the release of the estradiol in art and gelatin degradation while the effect of effect.
It is above-described, it is only presently preferred embodiments of the present invention, is not limited to the scope of the present invention, of the invention is upper
Stating embodiment can also make a variety of changes.What i.e. every claims and description according to the present patent application were made
Simply, equivalent changes and modifications, falls within the claims of patent of the present invention.The not detailed description of the present invention is
Routine techniques content.
Claims (12)
1. a kind of degradable inner membrane of uterine cavity implant system, including delivery pipe, push rod and implant, at least part push rod are contained in
In delivery pipe, implant is contained in delivery pipe and receives the promotion of push rod in the first state, and implant is with the membranaceous of medicine
Or laminated structure, implant include the medicine of the matrix and load of biodegradable material on the substrate, are provided with matrix
Connect the through hole of membranaceous or laminated structure both sides.
2. inner membrane of uterine cavity implant system according to claim 1, it is characterised in that the delivery pipe is circular tube structure, in it
Side wall is formed as step wall and limits the major diameter cavity and minor diameter cavity of connection.
3. inner membrane of uterine cavity implant system according to claim 2, it is characterised in that push rod is straight-bar structure, including first
Enlarged diameter section, reduced diameter section and the second enlarged diameter section, wherein, reduced diameter section be located at the first enlarged diameter section and the second enlarged diameter section it
Between, and the first enlarged diameter section is contained in major diameter cavity and coordinates.
4. inner membrane of uterine cavity implant system according to claim 1, it is characterised in that implant is ▽ types, Y types, orType.
5. inner membrane of uterine cavity implant system according to claim 1, it is characterised in that matrix is to be supported on degradable skeleton
Gelatin film or independent gelatin film.
6. inner membrane of uterine cavity implant system according to claim 5, it is characterised in that degradable skeleton is V-type.
7. inner membrane of uterine cavity implant system according to claim 1, it is characterised in that through hole is uniform with the spacing of 2mm-3mm
Ground is distributed.
8. inner membrane of uterine cavity implant system according to claim 1, it is characterised in that a diameter of 2mm-3mm of through hole.
9. inner membrane of uterine cavity implant system according to claim 1, it is characterised in that -7 exhausting hole of 5 row is set in matrix.
10. inner membrane of uterine cavity implant system according to claim 1, it is characterised in that Yin is blended for 17- β estradiol in medicine
The U.S. pungent joint of diindyl；Or single 17- β estradiol.
11. inner membrane of uterine cavity implant system according to claim 10, it is characterised in that the daily burst size of medicine is 20-
200μg。
12. inner membrane of uterine cavity implant system according to claim 1, it is characterised in that drug distribution is in the inside of matrix.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711340775.3A CN107951550A (en) | 2017-12-14 | 2017-12-14 | A kind of degradable inner membrane of uterine cavity implant system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711340775.3A CN107951550A (en) | 2017-12-14 | 2017-12-14 | A kind of degradable inner membrane of uterine cavity implant system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107951550A true CN107951550A (en) | 2018-04-24 |
Family
ID=61958960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711340775.3A Withdrawn CN107951550A (en) | 2017-12-14 | 2017-12-14 | A kind of degradable inner membrane of uterine cavity implant system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107951550A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110384830A (en) * | 2018-04-19 | 2019-10-29 | 易浦润（上海）生物技术有限公司 | Has the isolation film and preparation method thereof for reactivating inner membrance substrate layer function in a kind of uterine cavity |
| CN113262332A (en) * | 2018-04-19 | 2021-08-17 | 易浦润（上海）生物技术有限公司 | Elastic film |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102120059A (en) * | 2011-03-11 | 2011-07-13 | 东南大学 | Medicinal stent-graft for preventing and treating intrauterine adhesion |
| CN202843666U (en) * | 2012-10-26 | 2013-04-03 | 丁书贵 | Intrauterine anti-adhesion diaphragm |
| CN203074772U (en) * | 2013-02-01 | 2013-07-24 | 浙江大学医学院附属妇产科医院 | Absorbable anti-adhesion diaphragm in uterine cavity of uterus |
| CN103784244A (en) * | 2012-10-30 | 2014-05-14 | 饶永 | Intrauterine implant |
| CN204049793U (en) * | 2014-07-26 | 2014-12-31 | 徐大宝 | Intrauterine adhesion control device |
| CN206239777U (en) * | 2016-06-23 | 2017-06-13 | 刘芸 | Thing is inserted in uterus and the imbedding system of thing is inserted in uterus |
| CN106983918A (en) * | 2017-03-03 | 2017-07-28 | 北京博辉瑞进生物科技有限公司 | A kind of biological adherence preventing material, preparation method and applications |
| CN208573803U (en) * | 2017-12-14 | 2019-03-05 | 易浦润（上海）生物技术有限公司 | A kind of degradable inner membrane of uterine cavity implant system |
-
2017
- 2017-12-14 CN CN201711340775.3A patent/CN107951550A/en not_active Withdrawn
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102120059A (en) * | 2011-03-11 | 2011-07-13 | 东南大学 | Medicinal stent-graft for preventing and treating intrauterine adhesion |
| CN202843666U (en) * | 2012-10-26 | 2013-04-03 | 丁书贵 | Intrauterine anti-adhesion diaphragm |
| CN103784244A (en) * | 2012-10-30 | 2014-05-14 | 饶永 | Intrauterine implant |
| CN203074772U (en) * | 2013-02-01 | 2013-07-24 | 浙江大学医学院附属妇产科医院 | Absorbable anti-adhesion diaphragm in uterine cavity of uterus |
| CN204049793U (en) * | 2014-07-26 | 2014-12-31 | 徐大宝 | Intrauterine adhesion control device |
| CN206239777U (en) * | 2016-06-23 | 2017-06-13 | 刘芸 | Thing is inserted in uterus and the imbedding system of thing is inserted in uterus |
| CN106983918A (en) * | 2017-03-03 | 2017-07-28 | 北京博辉瑞进生物科技有限公司 | A kind of biological adherence preventing material, preparation method and applications |
| CN208573803U (en) * | 2017-12-14 | 2019-03-05 | 易浦润（上海）生物技术有限公司 | A kind of degradable inner membrane of uterine cavity implant system |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110384830A (en) * | 2018-04-19 | 2019-10-29 | 易浦润（上海）生物技术有限公司 | Has the isolation film and preparation method thereof for reactivating inner membrance substrate layer function in a kind of uterine cavity |
| CN113262332A (en) * | 2018-04-19 | 2021-08-17 | 易浦润（上海）生物技术有限公司 | Elastic film |
| CN110384830B (en) * | 2018-04-19 | 2022-06-17 | 易浦润（上海）生物技术有限公司 | Isolating membrane with function of reactivating intima-media basal layer in uterine cavity and preparation method thereof |
| CN113262332B (en) * | 2018-04-19 | 2022-06-24 | 易浦润（上海）生物技术有限公司 | Elastic film |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2016960B1 (en) | Medicament reservoirs for medical implants | |
| EP1389472B1 (en) | Endovascular implant having an active coating | |
| US7435256B2 (en) | Method and apparatus for controlled delivery of active substance | |
| US20090118818A1 (en) | Endoprosthesis with coating | |
| Ashton et al. | Polymeric endoaortic paving: Mechanical, thermoforming, and degradation properties of polycaprolactone/polyurethane blends for cardiovascular applications | |
| CN1655738A (en) | Drug eluting implantable medical device | |
| CN101199873A (en) | Medicament elution instrument nanometer class colon washer machineole drug releasing structure and preparing method thereof | |
| CN107951550A (en) | A kind of degradable inner membrane of uterine cavity implant system | |
| CN104013996A (en) | Drug eluting implantable medical device capturing progenitor endothelial cell | |
| CN104667346B (en) | A kind of preparation method and application of biodegradable nano-microspheres | |
| JP2002519139A (en) | Medical devices with porous surfaces for controlling drug release | |
| DE102008008926A1 (en) | System for introducing an intraluminal endoprosthesis and method of making such a system | |
| CN208573803U (en) | A kind of degradable inner membrane of uterine cavity implant system | |
| CN106726032A (en) | A kind of tubular tissue engineering rack of timing control release polyfunctional molecule and preparation method thereof | |
| McKittrick et al. | Development of a bioactive polymeric drug eluting coronary stent coating using electrospraying | |
| CN109982689A (en) | Delivery apparatus and its manufacturing method | |
| CN102271723A (en) | Tissue regeneration membrane | |
| CN110584851A (en) | Ultrasonic controlled-release grooved degradable microsphere drug-loaded stent and preparation method thereof | |
| CN108339159A (en) | Medicine coating and preparation method thereof | |
| US20100057219A1 (en) | Device surface design for better cell adhesion | |
| CN106620897B (en) | A kind of endoluminal stent material of anti-restenosis | |
| EP3278834A1 (en) | Method of producing transdermal absorption sheet | |
| EP3793589B1 (en) | Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation | |
| CN111588914A (en) | Medicine coating for interventional or implanted medical apparatus and preparation method thereof | |
| CN110548215A (en) | Nasal cavity implant and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180424 |